FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

Boston, MA, Suresnes, France, February 20 2024– Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news